No association of MDM2 SNP309 with risk of glioblastoma and prognosis

Soufiane El Hallani; Yannick Marie; Ahmed Idbaih; Mathieu Rodero; Blandine Boisselier; Florence Laigle-Donadey; François Ducray; Jean-Yves Delattre; Marc Sanson

doi:10.1007/s11060-007-9416-1

No association of MDM2 SNP309 with risk of glioblastoma and prognosis

J Neurooncol. 2007 Dec;85(3):241-4. doi: 10.1007/s11060-007-9416-1. Epub 2007 Jun 14.

Authors

Soufiane El Hallani¹, Yannick Marie, Ahmed Idbaih, Mathieu Rodero, Blandine Boisselier, Florence Laigle-Donadey, François Ducray, Jean-Yves Delattre, Marc Sanson

Affiliation

¹ INSERM, U711, Biologie des Interactions Neurones & Glie, Paris 75013, France.

PMID: 17568997
DOI: 10.1007/s11060-007-9416-1

Abstract

The MDM2 SNP309 variant has been shown to increase MDM2 expression and to be associated with tumor formation. In glioblastomas, the P53/MDM2 pathway is of crucial importance and MDM2 amplification is related to poor prognosis. However, we show here that MDM2 SNP309 is not associated with glioblastoma risk, and is not a prognostic factor.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Aged, 80 and over
Biomarkers, Tumor / genetics*
Brain Neoplasms / genetics*
Brain Neoplasms / mortality
Brain Neoplasms / pathology
Case-Control Studies
Female
Gene Expression Regulation, Neoplastic / genetics
Genetic Predisposition to Disease
Glioblastoma / genetics*
Glioblastoma / mortality
Glioblastoma / pathology
Humans
Male
Middle Aged
Polymorphism, Single Nucleotide
Prognosis
Proto-Oncogene Proteins c-mdm2 / genetics*
Reference Values
Risk Factors
Survival Analysis

Substances

Biomarkers, Tumor
MDM2 protein, human
Proto-Oncogene Proteins c-mdm2